retatrutide for diabetes Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide: A Promising Option for

Featuring BPC-157 peptide, BPC-157 is a peptide that helps alleviate joint pain, improve joint mobility, and boost recovery from injuries

Hu YL, Zhang YJ, Lv XY, Liu RL, Zhong ZH, Fu LJ et al (2024) Impact of Omicron variant infection on female fertility and laboratory outcomes: a self-controlled study

In recent coordinated actions, a coalition of 38 State AGs raised concerns regarding: products containing unknown contaminants or incorrect dosages

Well, the amount of research on capsaicin is still small, as is the amount of weight loss

What the research shows: A phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity